Table of Contents
| << Previous Issue | Oct 2025 (Vol: 2025, Issue: 10) | Next Issue >> |
- Section: Licensing
-
Novo Nordisk Expands Rare Disease Pipeline with US$2.4 B Omeros Partnership
- Section: Mergers & Acquisitions
-
Pfizer Expands Obesity Portfolio with US$4.9 B Acquisition of Metsera
-
Roche to Acquire 89bio and its FGF21 Analogue Lead Asset for US$3.5 B
-
BioCryst to Acquire Astria Therapeutics for up to US$700 M
-
Novo Nordisk Strengthens Metabolic Pipeline with US$5.2 B Acquisition of Akero Therapeutics
-
Genmab Strengthens Oncology Pipeline with US$8 B Acquisition of Merus
-
Bristol Myers Squibb to Acquire Orbital Therapeutics and its RNA Platform for US$1.5 B
- Section: Research & Development
-
Takeda Signs US$11.4 B Oncology Partnership with Innovent Biologics



RSS